The market is projected to grow from $11B in 2024 to $40B by 2030, driven by both conventional bispecifics and advancements such as antibody ... from early discovery to cell line development ...

For modern biotherapeutics, cell line development workflows must include more than just automated liquid handling.

Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...

With this model, researchers may be able to discover antibody drugs capable of targeting a wide range of infectious diseases.

Targeted therapies for high-risk leukemia in children have yet to be developed, but scientists at Université de Montréal and its affiliated Institute for Research in Immunology and Cancer are working ...

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced to ...

The demand for cell line development services is anticipated to grow at an ... An expanding range of applications, including drug discovery, biologics manufacturing, and personalized medicine, ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop ...

signing a new biobucks-heavy pact that aims to add another new antibody-drug conjugate (ADC) to its pipeline. Roche, which put billions on the line a year ago across several ADC pacts, has ...